On Thursday, Novavax Inc (NVAX) stock saw a decline, ending the day at $9.92 which represents a decrease of $-0.08 or -0.80% from the prior close of $10. The stock opened at $10 and touched a low of ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

A look at some of the Health Report correspondence this week.   You can email us at healthreport@abc.net.au ...

临床暂停的原因是，CIC 2期试验中，一名于2023年1月接受该疫苗的 非美国受试者自发报告了严重不良事件 （SAE）——运动神经病变。该试验于2023年7月完成，受试者于2024年9月报告SAE。

Dr. Aileen Marty, Infectious Disease Specialist and Professor at Florida International University, joins Bob Sirott to talk ...

Novavax Inc.’s stock tumbled 16% early Wednesday after the company said the FDA has placed a clinical hold on its ...

在一名临床试验参与者发生严重不良事件後，Novavax(NVAX.US)遭美国食品和药物管理局暂停其实验性流感疫苗的开发，该股股价周三下挫20%。

投资慧眼Insights - 辉瑞对手、美国疫苗制造商诺瓦瓦克斯Novavax年中因与制药巨头赛诺菲的合作而逆转疫情后颓势，创下两日股价暴涨200%的「重生」传奇。而该公司近日因实验安全问题被美国FDA暂停临床试验，股价闪崩近20%。 周三（10月16日），诺瓦瓦克斯表示，在一名美国境外的试验参与者发生了严重运动神经病变后，美国食品药品监督管理局FDA暂停了这家公司的「流感/新冠联合疫苗」临床试验 ...

Novavax's shares are tumbling after the company disclosed that regulators paused clinical trials for two key vaccine ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the U.S. Food and Drug Administration (FDA) has placed a ...

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novavax, Inc. (“Novavax” or ...

Novavax shares tumbled after the Food and Drug Administration put a clinical hold on its testing applications for a combined ...